| Oluronke Akinrolabu, RN | |
|
1640 Powers Ferry Rd Se Unit 300, Marietta, GA 30067-5491 | |
| (877) 711-3418 | |
| Not Available |
| Full Name | Oluronke Akinrolabu |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 1640 Powers Ferry Rd Se Unit 300, Marietta, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144089632 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN284618 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Oluronke Akinrolabu, RN 202 Heritage Club Cir, Dallas, GA 30132-7541 Ph: (732) 552-5100 | Oluronke Akinrolabu, RN 1640 Powers Ferry Rd Se Unit 300, Marietta, GA 30067-5491 Ph: (877) 711-3418 |
News Archive
Many countries across the globe are experiencing a sharp surge in COVID-19 cases, with the total global case toll reaching more than 25.86 million. Face masks have become one of the most effective means to combat the virus spread, particularly if used in combination with regular hand hygiene and physical distancing.
A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.
LifeMap Solutions, Inc., a medical technology startup focused on creating innovative mobile health (mHealth) products and services powered by big data, today announced an initial $5 million seed round led by parent company LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., with additional participation via in-kind support from its development partner, the Icahn School of Medicine at Mount Sinai.
Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial.
› Verified 7 days ago
Kendra Shearer, REGISTRED NURSE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1241 Channel Park Sw, Marietta, GA 30064 Phone: 404-423-2370 Fax: 770-573-7308 | |
Sarika Mishra, NP Registered Nurse Medicare: Medicare Enrolled Practice Location: 400 Tower Rd Ne Ste 200, Marietta, GA 30060 Phone: 770-422-1372 Fax: 770-999-2488 | |
Mrs. Rhonda Kim Lee, NP-C Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 677 Church St Ne, Marietta, GA 30060 Phone: 770-793-7173 | |
Nancy Marie Certain, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1640 Powers Ferry Rd, Bldg 7, Suite 300, Marietta, GA 30067 Phone: 770-988-9200 Fax: 770-988-9296 | |
Chasity Goodin-anderson, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2901 Horseshoe Bend Rd Sw, Marietta, GA 30064 Phone: 770-685-4023 | |
Ms. Evelyn Kay Hale, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 677 Church St Ne, Marietta, GA 30060 Phone: 770-793-9560 | |
Mrs. Barbara Adelfa Rico-eccles, REGISTERED NURSE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 2611 Naylor Hall, Marietta, GA 30066 Phone: 678-994-1453 |